$100,000 of HEARTFLOW INC. lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to physician payments; issues related to Medicare reimbursement; issues related to Medicare reimbursement of AI-enabled technology; Ensuring Patient Access to Critical Breakthrough Products Act (S. 1717/H.R. 5343); Health Tech Investment Act (S. 1399/H.R. 6197); H.R. 9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, issues related to health care, generally."
You can find more data on corporate lobbying on Quiver Quantitative.
HTFL Insider Trading Activity
HTFL insiders have traded $HTFL stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $HTFL stock by insiders over the last 6 months:
- CAPITAL LIFE SCIENCES INVESTORS, LLC BAIN has made 0 purchases and 5 sales selling 4,000,000 shares for an estimated $114,998,336.
- CAMPBELL ROGERS (Chief Medical Officer) has made 0 purchases and 5 sales selling 212,657 shares for an estimated $5,341,991.
- JOHN C.M. FARQUHAR (Chief Executive Officer) has made 0 purchases and 8 sales selling 174,272 shares for an estimated $5,044,038.
- JULIE A CULLIVAN has made 0 purchases and 2 sales selling 17,122 shares for an estimated $446,610.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
HTFL Hedge Fund Activity
We have seen 109 institutional investors add shares of HTFL stock to their portfolio, and 38 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 6,088,213 shares (+103.3%) to their portfolio in Q1 2026, for an estimated $148,126,222
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC removed 2,000,000 shares (-16.1%) from their portfolio in Q1 2026, for an estimated $48,660,000
- SCHUSTERMAN INTERESTS, LLC removed 1,679,535 shares (-86.6%) from their portfolio in Q1 2026, for an estimated $40,863,086
- BAMCO INC /NY/ added 1,523,654 shares (+66.1%) to their portfolio in Q1 2026, for an estimated $37,070,501
- CAPRICORN INVESTMENT GROUP LLC removed 1,404,900 shares (-84.6%) from their portfolio in Q1 2026, for an estimated $34,181,217
- FMR LLC added 1,274,949 shares (+30.9%) to their portfolio in Q1 2026, for an estimated $31,019,509
- MILLENNIUM MANAGEMENT LLC added 1,025,648 shares (+1513.4%) to their portfolio in Q1 2026, for an estimated $24,954,015
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
HTFL Analyst Ratings
Wall Street analysts have issued reports on $HTFL in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 05/04/2026
- Wells Fargo issued a "Overweight" rating on 01/28/2026
To track analyst ratings and price targets for HTFL, check out Quiver Quantitative's $HTFL forecast page.
HTFL Price Targets
Multiple analysts have issued price targets for $HTFL recently. We have seen 4 analysts offer price targets for $HTFL in the last 6 months, with a median target of $37.0.
Here are some recent targets:
- Gene Mannheimer from Freedom Capital Markets set a target price of $37.0 on 07/01/2026
- Larry Biegelsen from Wells Fargo set a target price of $37.0 on 05/15/2026
- William Plovanic from Canaccord Genuity set a target price of $37.0 on 05/15/2026
- Robbie Marcus from JP Morgan set a target price of $35.0 on 03/19/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
